-- Scott Roberts
FRIDAY, May 20 (HealthDay News) -- Edurant (rilpivirine), in
combination with other antiretroviral drugs, has been approved by
the U.S. Food and Drug Administration to treat HIV-1 infection in
adults who haven't taken any prior HIV therapy
HIV is the virus that causes AIDS. Edurant, a so-called
non-nucleoside reverse transcriptase inhibitor (NNRTI), blocks the
virus's ability to reproduce itself. The pill is taken once daily
with food, the FDA said in a news release.
Edurant was evaluated in a pair of 48-week studies involving
1,368 adults infected with HIV. Compared to another NNRTI,
efavirenz, Edurant was as effective in lowering amounts of the
virus in a person's blood, the agency said.
The most common adverse reactions reported were depression,
insomnia, headache and rash.
Since Edurant does not reverse HIV infection, people must
continue taking the drug, in combination with other anti-HIV
medications, to prevent HIV-related illness, the FDA said.
Edurant is produced by Tibotec Therapeutics, based in Raritan,
aids.gov to learn more
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.